74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Karyopharm Therapeutics Inc
Closed
SectorHealthcare
3.99 13.35
Overview
Share price change
24h
Min
3.47
Max
4.02
Income | 1.3M -31M |
|---|---|
Sales | -8.2M 31M |
EPS | -0.24 |
Profit margin | -100.779 |
Employees | 279 |
EBITDA | 972K -20M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +1230.05% upside |
Market Cap | 31M |
|---|---|
Previous open | -9.36 |
Previous close | 3.99 |
News Sentiment
By Acuity
37%
63%
130 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
Karyopharm Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Karyopharm Therapeutics Inc Forecast
Price Target
By TipRanks
1230.05% upside
12 Months Forecast
Average 54 USD 1230.05%
High 105 USD
Low 15 USD
Based on 6 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
130 / 386 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
